US 4,960,413 AGrant

Wound Dressing

Issue Date:1990-10-02

•13 Claims

•1 Drawing Sheets

Abstract

There is disclosed a wound dressing comprised by an assembly of microfungal fibres which have been treated with alkali to expose chitin and chitosan. The fibres may be derived from hyphae or from sporangiophores. The assembly may include other fibres, may be bleached and incorporate other additives such as silver as an anti-bacterial agent.

Metadata

Assignee

The Shirley Institute

Inventors

Brian Sagar
Paul Hamlyn
David Wales

Application Information

Application Number:US 3099717

Filing Date:1989-02-13

Priority Date:1987-05-19

Art Unit:336

Classifications

IPC:

A61M 3500

Field of Search:

604424128514536289;304443-44715655;77920

Patent Drawings (1 sheets)

Description

The invention will be further apparent from the following description which concerns by way of example only the preparation of various forms of wound dressing embodying same and with reference to the accompanying drawings, in which:

FIG. 1 is a diagrammatic illustration of a batch process for preparing a first form of wound dressing;

FIG. 2 is a diagrammatic illustration of a batch process for making a second form of wound dressing; and

FIG. 3 is a diagrammatic illustration of a continuous process for making the second form of wound dressing.

Referring firstly to FIG. 1, micro-fungal mycelia are produced from a culture of Mucor mucedo (CMI 184 726), grown in a nutrient solution containing malt extract (17q/1) and mycological peptone (3g/1) in a fermenter vessel 10 at a temperature of 30.degree. C. for one to two days.

The culture is then washed and treated with a 2N boiling solution of sodium hydroxide for one hour to dissolve protein from the outer layers of the cell walls and expose the underlying chitin and chitosan. Further de-acetylisation of the chitin may be effected by 40% sodium hydroxide solution.

The culture is repeatedly washed until neutral pH is obtained and then bleached by treatment with a solution of hydrogen peroxide (80 ml/1 37% H.sub.2 O.sub.2 + 40 g/1 NaOH + 40 g/1 sodium silicate) for two hours at room temperature.

The culture is washed again and disintegrated using normal paper making equipment 11 to ensure an even dispersion of the hyphae in water to form a slurry. The slurry is strained through a filter medium 12 to leave a wet-laid matt 13 having a thickness of 1 mm or thereabouts.

If desired other fibres having wound healing properties such as of collagen or an alginate or both may be mixed with the hyphae before the matt is laid, as may textile fibres to give mechanical strength or other properties.

Suitably sized portions 14 for wound dressings of desired size are cut from the matt 13 and immediately encapsulated whilst still wet in airtight packs 15 and subsequently sterilised. The retained water acts as a plasticiser to prevent the hyphae from becoming dry and brittle and also ensures that the dressings are moist when removed from the packs for use.

Alternatively glycerol or polyethylene glycol may be added to the slurry before the matt is laid.

In another example Mucor mucedo is replaced by Rhizomucor miehei (CMI 147 066) which is fermented at 50.degree. C.

In yet another example sporangiophores of Phycomyces blakesleeanus (CBS 283 35) are grown in static culture, harvested and introduced to the vessel 10 for the alkali and subsequent treatments.

As shown in FIG. 2, the slurry from vessel 10 may be poured in to shaped moulds or dishes 20 which are then frozen in a deep freezer 21 for say sixteen hours and then freeze-dried for twenty-eight hours in a freeze-drier 22. Absorbent pads typically of say 10 cms in diameter or larger and from a few millimeters to several centimeters thick can be produced in this way.

FIG. 3 illustrates a continuous process for producing a web in which the slurry is laid down using conventional paper making machinery 30 and passed straight into a continuous freezer 31 and from there into a continuous freeze drying plant 32 after which the resulting matt 33 can be rolled up as at 34.

It is surprising that the matt is so flexible and strong as to permit this since, previously, 100% fungal matts have been brittle unless plasticiser has been added.

Use of a plasticiser in freeze-dried wound dressings is not necessary but a plasticiser may of course be added if desired.

It will be appreciated that it is not intended to limit the invention to the above example only, many variations, such as might readily occur to one skilled in the art, being possible, without departing from the scope thereof as defined by the appended claims.

Thus for example, the matts or pads or fibres from which they are formed may be treated in a solution of silver nitrate whereby silver ions will be captured by the chitosan and thus be present in the dressings as an anti-bacterial agent.

Again for example, the dressings may be treated with a bi-functional cross-linking agent such as glutaraldehyde.

Yet again, for example the wet-laid matts may be laminated with one or more backing layers of conventional, textile fibre if desired.

Tests carried out by Royal National Orthopaedic Hospital at Stamore Middlesex, indicated that wound dressings prepared in accordance with the invention from Mucor mucedo gave encouraging results in terms of the quality and quantity of repair tissue.

Claims

We claim:

1. A wound dressing comprising an assembly of microfungal fibers which have been treated with alkali to dissolve protein from the outer layers of the cell walls and expose chitin and chitosan.

2. A wound dressing according to claim 1 wherein the microfungal fibers are hyphae.

3. A wound dressing according to claim 1 wherein the microfungal fibers are sporangiophores.

4. A wound dressing according to claim 1 wherein the assembly is a wet-laid mat.

5. A wound dressing according to claim 4 wherein the wet-laid mat includes a plasticiser.

6. A wound dressing according to claim 5 wherein said plasticiser is water.

7. A wound dressing according to claim 1 wherein the assembly is frozen and freeze-dried.

8. A wound dressing according to claim 1 wherein the assembly is cut to a desired size and sealed in a water vapour impermeable pack.

9. A wound dressing according to claim 1 wherein the microfungal fibers are bleached.

10. A wound dressing according to claim 1 wherein other fibers are included with the microfungal fibres.

11. A wound dressing according to claim 1 wherein the alkali treated fibers are treated with a silver salt whereby silver ions are captured and present in the dressing as an anti-bacterial agent.

12. A wound dressing according to claim 1 wherein the assembly is treated with a bi-functional cross-linking agent.

13. A wound dressing according to claim 1 wherein the assembly is laminated with one or more backing layers of conventional textile material.

Patent Citations (24)

Patent	Date	Inventor
US2040880	1936-05-01	Rigby
US2459897	1949-01-01	Schwarz
US2512616	1950-06-01	Eberl et al.
US2688586	1954-09-01	Eberl et al.
US2910408	1959-10-01	Pope et al.
US3052237	1962-09-01	Chand
US3196075	1965-07-01	Neuhauser
US3533940	1970-10-01	Peniston et al.
US3879168	1975-04-01	Franklin et al.
US3903268	1975-09-01	Balassa
US4363319	1982-12-01	Altshuler
US4373519	1983-02-01	Errede et al.
US4391799	1983-07-01	Mason Jr. et al.
US4421583	1983-12-01	Aldred et al.
US4524064	1985-06-01	Nambur
US4532134	1985-07-01	Malette et al.
US4562110	1985-12-01	Tong
US4570629	1986-02-01	Widra
US4572906	1986-02-01	Sparkes et al.
US4651725	1987-03-01	Kifive et al.
US4659700	1987-04-01	Jackson
US4699135	1987-10-01	Motosugi et al.
EPX199531	1986-10-01
EPX200574	1986-11-01

Non-Patent Literature (2)

"Innovations that Enrich the Material World"--Laboratory News 3, Oct. 1988.
"Production and Isolation of Chitosan from Mucor rouzii", Applied and Environmental Microbiology, Aug. 1979, pp. 323-328.

Abstract

Description